Pyxis Oncology is trading 5.6% down today at $2.52, extending the volatility that followed its late-June private placement of up to $114 million in stock and warrants.
- The stock remains under pressure following a recent financing deal involving a private placement of stock and warrants.
- Biotech stocks are broadly selling off alongside weaker risk assets as heightened U.S.-Iran geopolitical tensions drive a risk-off tone in growth sectors.